Climb Bio, Inc.
CLYMDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
budoprutug | Phase 2 | Primary Membranous Nephropathy | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Climb Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Climb Bio, Inc.'s (CLYM) pipeline across Phase 2. Its lead program is budoprutug (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Climb Bio, Inc.'s next FDA catalyst?→
Climb Bio, Inc.'s (CLYM) next tracked catalyst is a Earnings expected November 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CLYM biotech catalysts?→
Add CLYM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Climb Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.